Distinguished in Astrocytoma

Elizabeth C. Moyal

Toulouse, FR 
Distinguished in Astrocytoma
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Elizabeth Moyal practices in Toulouse, France. Ms. Moyal is rated as a Distinguished expert by MediFind in the treatment of Astrocytoma. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles and participated in 2 clinical trials in the study of Astrocytoma.

Gender
Female

Locations

Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2024
Intervention Type: Radiation, Drug
Study Drugs: 2-hydroxyoleic Acid, Temozolomide
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

26 Total Publications

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancer.
Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancer.
Journal: International journal of cancer
Published: December 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Moyal's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile